Cas:42232-93-9 Dodecanyl heneicosanoate manufacturer & supplier

Chemical Name:Dodecanyl heneicosanoate

CAS.NO:42232-93-9

Synonyms:Dodecanyl heneicosanoate

Molecular Formula:C₃₂H₆₆O₂

Molecular Weight:494

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Dodecanyl heneicosanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dodecanyl heneicosanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Dodecanyl heneicosanoate Use and application,Dodecanyl heneicosanoate technical grade,usp/ep/jp grade.

Related News: On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks. Dodecanyl heneicosanoate manufacturer Roche’s second anti-tau antibody UCB0107, partnered with UCB, is also slated to enter deeper testing this year. Tau had appeared to have fresh promise as a rival of sorts to amyloid. Tau theory goes that neurofibrillary tangles that form inside cells clog up the brain, and clearing this can help Alzheimer’s patients. Dodecanyl heneicosanoate supplier The survival benefit is “unprecedented” for an aging myeloma population, almost all of whom were 65 years of age or older, said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. Dodecanyl heneicosanoate vendor The survival benefit is “unprecedented” for an aging myeloma population, almost all of whom were 65 years of age or older, said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. Dodecanyl heneicosanoate factory Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.